Acuity

The lead program, ABC103, is a combination product using a synthetic polymer implant to deliver paclitaxel locally at the surgical site to prevent non-small cell lung cancer recurrence. It received FDA orphan drug designation and was scheduled for Phase I clinical trials in late 2019. The technology was acquired by Cook Biotech in June 2023. ABC103 will use Cook Biotech’s proprietary extracellular matrix (ECM) technology and is a platform technology designed for localized, sustained drug delivery to prevent post-surgical lung cancer recurrence. It combines approved/cleared surgical staple-line buttress, drug-eluting polymers and paclitaxel. Cook Biotech has expanded its technology portfolio by acquiring the assets of AcuityBio. No published clinical results available.